Security Snapshot

Zenas BioPharma, Inc. - Common Stock (ZBIO) Institutional Ownership

CUSIP: 98937L105

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

108

Shares (Excl. Options)

51.63MFull value: 51,626,349 · shares · 30 Sep 2026

Price

$26.97

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+5,733,672
Value change
+$155,517,307
Number of holders
108
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
65,276,927
SEC-reported price per share
$28.76
Insider filing price
$28.76
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ZBIO - Zenas BioPharma, Inc. - Common Stock is tracked under CUSIP 98937L105.
  • 108 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 143 to 108 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.55BFull value: $1,548,569,766 · USD · 30 Jun 2026
    to
    $1.39BFull value: $1,392,434,151 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 108 institutions filings for Q3 2026.

Open SEC evidence

Security key

98937L105

13F reference period

Q3 2026

13F holders

108

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
ZBIO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 12% +23% $228,098,473 +$43,064,817 8,094,339 +23% Wellington Management Group LLP 30 Sep 2026
FMR LLC 14% +30% $277,876,336 +$109,228,632 7,652,255 +65% FMR LLC 31 Dec 2025
InnoCare Pharma Inc. 10% +11% $217,630,000 +$62,180,000 7,000,000 +40% InnoCare Pharma Inc. 26 Aug 2026
SR ONE CAPITAL MANAGEMENT, LLC 7.7% -19% $148,264,043 5,037,854 0% SR One Capital Management, LLC 13 Aug 2026
BlackRock, Inc. 5% $88,651,285 3,287,021 BlackRock, Inc. 30 Sep 2026
Enavate Sciences GP, LLC 4.9% -34% $100,899,610 -$20,947,043 3,245,404 -17% Enavate Sciences GP, LLC 19 Aug 2026
MOULDER LEON O JR 5.1% +6% $67,767,315 +$4,017,777 3,220,880 +6.3% MOULDER LEON O JR 29 Apr 2026
Longitude Capital Partners IV, LLC 4.9% $58,425,578 2,631,522 Patrick G. Enright 09 Oct 2025
Novo Holdings A/S 4.7% -12% $44,400,000 -$4,772,267 2,000,000 -9.7% Novo Holdings A/S 30 Sep 2025
Xencor Inc 1.5% $28,180,000 1,000,000 Xencor, Inc. 30 Sep 2026
As of 30 Sep 2026, 108 institutional investors reported holding
51.63MFull value: 51,626,349 · shares · 30 Sep 2026
shares of Zenas BioPharma, Inc. - Common Stock (ZBIO). This represents 79% of the company’s total
65.28MFull value: 65,276,927 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
72%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
WELLINGTON MANAGEMENT GROUP LLP 12% 8,094,339 0.04% $218,304,324
SR ONE CAPITAL MANAGEMENT, LP 7.7% 5,037,854 12% $135,870,922
NEA Management Company, LLC 6.2% 4,023,219 8% $108,506,217
FEDERATED HERMES, INC. 4.8% 3,107,308 0.12% $83,804,097
Capital International Investors 4.5% 2,925,343 0.02% $78,896,501
ENAVATE SCIENCES GP, LLC 4.5% 2,919,159 28% $78,729,718
Polar Capital Holdings Plc 3.7% 2,405,374 0.18% $64,872,937
Royalty Pharma Sub-Manager, LLC 3.7% 2,388,150 33% $64,408,406
Fairmount Funds Management LLC 3.6% 2,371,358 4% $63,955,525
STATE STREET CORP 2.9% 1,882,634 0% $50,774,639
NVP ASSOCIATES, LLC 2.8% 1,838,482 18% $49,583,860
VANGUARD CAPITAL MANAGEMENT LLC 2.6% 1,722,706 0% $46,461,381
ALLIANCEBERNSTEIN L.P. 1.6% 1,060,539 0.01% $28,602,737
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,060,277 0% $28,604,081
TWO SIGMA INVESTMENTS, LP 1.3% 833,288 0.02% $22,473,777
EcoR1 Capital, LLC 1.2% 789,500 1% $21,292,815
GOLDMAN SACHS GROUP INC 1.2% 774,621 0% $20,891,529
BANK OF AMERICA CORP /DE/ 1% 683,308 0% $18,428,817
Woodline Partners LP 0.91% 590,969 0.05% $15,938,434
ArrowMark Colorado Holdings LLC 0.81% 527,976 0.68% $14,239,513
Rock Springs Capital Management LP 0.77% 502,077 0.73% $13,541,017
NEXTBio Capital Management LP 0.65% 426,736 4.9% $11,509,070
Vestal Point Capital, LP 0.61% 395,000 0.28% $10,653,150
VANGUARD PORTFOLIO MANAGEMENT LLC 0.59% 384,150 0% $10,360,526
SILVERARC CAPITAL MANAGEMENT, LLC 0.51% 334,057 1.1% $9,009,517

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 51,626,349 $1,392,434,151 +$155,517,307 $26.97 108
2026 Q2 61,266,969 $1,548,569,766 +$88,389,128 $25.38 143
2026 Q1 56,887,525 $1,112,055,053 +$218,738,134 $19.55 138
2025 Q4 41,561,367 $1,504,857,337 +$255,199,550 $36.31 118
2025 Q3 34,774,383 $771,813,059 +$23,276,708 $22.20 78
2025 Q2 34,055,191 $329,977,952 +$15,611,752 $9.69 72
2025 Q1 32,489,801 $256,715,238 +$5,759,402 $7.90 67
2024 Q4 31,699,756 $259,632,936 +$20,083,837 $8.19 65
2024 Q3 24,771,152 $418,526,187 +$418,475,122 $16.92 44
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .